Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trialSimon Parlow, Rebecca Mathew, Baylie Morgan et al.|American Heart Journal|2023Cited by 17
INOTROPE VERSUS PLACEBO THERAPY IN CARDIOGENIC SHOCK: THE CAPITAL DOREMI2 TRIALSimon Parlow, Rebecca Mathew, Pietro Di Santo et al.|Canadian Journal of Cardiology|2023Cited by 0
INOTROPE VERSUS PLACEBO THERAPY IN CARDIOGENIC SHOCK: THE CAPITAL DOREMI2 TRIALSimon Parlow, Rebecca Mathew, Pietro Di Santo et al.|Canadian Journal of Diabetes|2023Cited by 0